Background: Molecular diagnostic tests may improve antibiotic prescribing by enabling earlier tailoring of antimicrobial therapy. However, clinicians’ trust and acceptance of these tests will determine their application in practice.
Objectives: To examine ICU prescribers’ views on the application of molecular diagnostics in patients with suspected hospital-acquired and ventilator-associated pneumonias (HAP/VAP).
Methods: Sixty-three ICU clinicians from 5 UK hospitals completed a cross-sectional questionnaire between May-July 2020 assessing attitudes towards using molecular diagnostics to inform initial agent choice and to help stop broad-spectrum antibiotics early.
Results: Attitudes towards using molecular diagnostics to inform initial treatment choices and to stop broad-spectrum antibiotics early were nuanced. Most (83%) were positive about molecular diagnostics, agreeing that using results to inform broad-spectrum antibiotics prescribing is good practice. However, many (58%) believed sick patients are often too unstable to risk stopping broad-spectrum antibiotics based on a negative result.
Conclusions: Positive attitudes towards the application of molecular diagnostics to improve antibiotic stewardship were juxta-positioned against the perceived need to initiate and maintain broad-spectrum antibiotics to protect unstable patients.